Mentor Corp, supplier of medical products for the global aesthetic market, announced that subject enrollment and initial dosing in its pivotal Phase IIIb study of its investigational botulinum toxin type A for the reduction of glabellar rhytides (frown lines) by intramuscular injection has been completed. Enrollment in the IIIb trial, which consisted of 700 subjects, began in late November and was completed in mid-January.

"We are very excited about the rapid completion of subject enrollment in Phase IIIb of our botulinum toxin clinical trial," says Joshua H. Levine, president and chief executive officer of Mentor Corp. "Our investigators observed strong subject interest in the study drug and this leads us to believe that the market is primed for new products focused on the large and rapidly growing cosmetic application."

Joel Schlessinger, a board certified physician in dermatology and cosmetic surgery and President emeritus of American Society of Dermatology and current President of Aesthetic Surgery is very impressed with the results with the formulation of botulinum toxin.

"There is a significant amount of interest and excitement about new products being developed for the cosmetic indication focused on the reduction of glabellar rhytides (frown lines)," says Schlessinger.

[www.medicalnewstoday.com, January 31, 2008]